Media Summary: Sara Tolaney, MD, MPH, Dana-Farber Cancer Institute, Boston, MA, provides an overview of a biomarker analysis of the Phase III ... Dr Jane Meisel comments on Dr Hope Hugo's study on the use of Filipa Lynce, MD, provides an overview of a study at Dana-Farber Cancer Institute evaluating the safety and
Sacituzumab Govitecan Effective For Hr - Detailed Analysis & Overview
Sara Tolaney, MD, MPH, Dana-Farber Cancer Institute, Boston, MA, provides an overview of a biomarker analysis of the Phase III ... Dr Jane Meisel comments on Dr Hope Hugo's study on the use of Filipa Lynce, MD, provides an overview of a study at Dana-Farber Cancer Institute evaluating the safety and Sara Tolaney, MD, MPH, Dana-Farber Cancer Institute, Boston, MA, provides an overview of the Phase III ... Sara Tolaney, MD, MPH, Dana-Farber Cancer Institute, Boston, MA, discusses the final overall survival (OS) analysis of the Phase ... Sara Tolaney, MD, MPH, Dana-Farber Cancer Institute, Boston, MA, provides an overview of the rationale and trial design of the ...
At this year's European Society for Medical Oncology (ESMO) Congress in Madrid, Spain, Dr. Kevin Kalinsky, Director of the Glenn ... Dr Hope Rugo speaks to ecancer about the use of Prof Hope Rugo speaks to ecancer on the overall survival results from the phase III TROPiCS-02 study of Listen to a soundcast of the February 3, 2023, FDA approval of Trodelvy ( Scott Tagawa, MD, MS, FACP, Weill Cornell Medical Center, New York, NY, takes us through a study which evaluated the efficacy ... Arlene Siefker-Radtke, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the recent press ...
